CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 60 target
Drug / intervention
Intravitreal injections of ziv-afliberceptdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02556723
NCT02556723N/ACompleted
CompareCT.gov

Intravitreal Injections of Ziv-aflibercept for Macular Diseases: Diabetic Macular Edema, Wet AMD and Macular Edema Secondary to Vein Occlusons

Retina Clinic, Sao Paulo, Brazil·interventional·Posted Sep 22, 2015·Updated Oct 4, 2016

In Brief

A clinical study evaluating Intravitreal injections of ziv-aflibercept for Diabetic Macular Edema and 3 related conditions. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Diabetic macular edema (DME), wet-AMD and macular edema secondary to vein occlusions are the leading cause of blindness in developed countries. Several therapies have been studied as such laser treatment and intravitreal injections of corticosteroids or anti-VEGF drugs. In terms of public health the long term treatment with the current available drugs is very expensive and new therapies with the same or better effect should be investigated. This study intends to evaluate the efficacy and safety of intravitreal injections of ziv-aflibercept for the treatment of patients with DME, wet-AMD and macular edema secondary to vein occlusions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema, Age Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema, Central Retinal Vein Occlusion With Macular Edema
CountriesBrazil
CollaboratorsFederal University of São Paulo

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 22, 2015
Enrollment StartSep 1, 2014
Primary CompletionSep 1, 2015
Study CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 10.8 years ago

Interventions

Intravitreal injections of ziv-afliberceptdrug

All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks. No topical or systemic antibiotics will be prescribed (pre- injection or postinjection).